Menu
- I See Blood Cancer
- Patient discussions
Menu
Treating Waldenström's macroglobulinemia
Defining your patient's treatment plan
Defining your patient's treatment plan
Find out what your next steps should be in planning your patient’s treatment
The history of WM: from first definition to current advances and expectations for the future
From the first description in 1944 by the Swedish hematologist Jan Waldenström, to the evolutions in management and treatment, with a look to possible future developments.
CP-299792, approved on 11/05/2022
Indications for treatment initiation in patients with WM[1]
Clinical
These clinical symptoms are indications treatment should be initiated in your patient:
- Recurrent fever, night sweats, weight loss, fatigue
- Hyperviscosity
- Lympthadenopathy: either symptomatic or bulky (maximum diameter of at least 5 cm)
- Symptomatic hepatomegaly and/or splenomegaly
- Symptomatic organomegaly and/or organ or tissue infiltration
- Peripheral neuropathy due to WM
Laboratory
If your patient displays the following laboratory findings, treatment should be initiated:
- Symptomatic cryoglobulinaemia
- Symptomatic cold agglutinin anaemia
- Autoimmune haemolytic anaemia and/or thrombocytopaenia
- Nephropathy related to WM
- Amyloidosis related to WM
- Hb ≤10 g/dL
- Platelets <100x109/L
- IgM levels >60 g/L
The ESMO guidelines for the management of WM outline clinical and laboratory indications for treatment initation.[1]
To treat or not to treat?
Patients with low Hb levels, high lymphoplasmacytic cell infiltration, IgM flare and high ß2-microglobulin levels may be at higher risk for development of symptomatic WM.[2][3]
However, patients may be asymptomatic for 5–10 years and can be managed with a ‘watch and wait’ approach, without treatment and should be followed up every 3-6 months.[1][2][3]
No data exist to support early initiation of therapy over a watch and wait strategy, nor is the level of monoclonal IgM alone an indication to start treatment.[1]
Hyperviscosity is a clinical emergency. Plasmapheresis should be used immediately in patients with symptomatic hyperviscosity, in addition to appropriate systemic therapy for WM.[1]
Additional tests
Additional work-up is often based on symptomatic presentation and laboratory findings that can indicate the need for treatment initiation.[4]
Clinically-indicated diagnostic work-up[4]
Types of WM treatment
For asymptomatic patients with acceptable IgM blood levels, no treatment is required. These patients will be monitored and seen by their clinic every 3–6 months for review.[5]
This course of action may seem confusing at first, but as there is no evidence that treating early in asymptomatic patients is beneficial, ‘watch and wait’ is applied in order to maintain the patient’s quality of life.[5]
Treatment will begin if the patient:[5]
- Develops WM-related symptoms
- Has elevated levels of IgM protein in the blood or they experience hyperviscosity
- Experiences changes in blood count (e.g. anaemia)
- Develops other complications (e.g. progressive neuropathy, cryoglobulinaemia or cold agglutinin disease)
Treatment may be required to treat WM symptoms and side effects of WM treatment, which include:[6]
- Plasmapheresis, when a patient has high levels of IgM resulting in hyperviscosity
- Blood transfusions or platelet transfusions to combat low blood or low platelet counts
- Immunoglobulin replacement therapy, for patients with low antibody levels
- Antibiotics or antiviral drugs, to prevent infections
There are a range of different treatment options for WM patients[5][^6]:
- Chemotherapy, given orally, intravenously or subcutaneously
- Steroids, often used in conjunction with chemotherapy
- Monoclonal antibody therapy
- Biological therapies
- Stem cell transplantation
- CAR T-cell therapy
Treatment selection should then be directed by the overall health of your patient, tumour burden, and clinical presentation.[1] Guideline therapy recommendations should be considered in conjunction with local practices and available treatment options.
Follow-up after WM treatment
Patients are monitored every 3–6 months after finishing treatment, possibly requiring further tests to assess their disease state. If they relapse from WM remission, depending on the response to their first-line treatment, this could be repeated, or they can be put in a second-line of treatment.[6]
Learn about the steps involved in diagnosing your patients’ WM
Find out more about discussing WM with your patients
Download this information on treating Waldenström’s macroglobulinemia
Download this information on treating Waldenström’s macroglobulinemia
CAR T-cell=chimeric antigen receptor T-cell; ESMO=European Society for Medical Oncology; IgM=immunoglobulin M; Hb=haemoglobin; WM=Waldenström’s macroglobulinemia.
This site has been developed by Janssen-Cilag International NV. Janssen-Cilag International NV is the responsible editor of this document.
CP-343204 - September 2022
